Although immune checkpoint inhibitors against programmed death‑1 (PD‑1) and its ligand (PD‑L1) have demonstrated promising results in several solid malignancies, including cervical cancer, there are some limitations to using PD-L1 immunohistochemical expression as a predictive biomarker for selecting patients who may benefit from such therapy.